NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...

Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...

Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage study of its investigational candidate, NUC-7738, in combination with ...

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company’s ...

NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98. However ...

As of 09:30 CEST. Market open. On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00.

Seven of the 12 patients had a progression-free survival time of over five months. Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in ...